DSpace at RU >

Browsing by Author Hagenbeek, A.

Full Text	Issue Date	Title	Author(s)
	2011	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.	Salles, G.; Jong, D. de; Xie, W.; Rosenwald, A.; Chhanabhai, M., et al
	2010	BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.	Oers, M.H. van; Tonnissen, E.L.R.T.M.; Glabbeke, M. van; Giurgea, L.; Jansen, J.H., et al
	2009	Allogene stamceltransplantatie in Nederland	Schattenberg, A.V.M.B.; Schouten, H.C.; Verdonck, L.F.; Willemze, R.; Lelie, J. van der, et al
	2009	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.	Veer, M.B. van 't; Jong, D.J. de; MacKenzie, M.A.; Kluin-Nelemans, H.C.; Oers, M.H. van, et al
	2009	Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.	Jong, D.J. de; Koster, A.; Hagenbeek, A.; Raemaekers, J.M.M.; Veldhuizen, D., et al
	2009	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.	Heutte, N.; Flechtner, H.H.; Mounier, N.; Mellink, W.A.M.; Meerwaldt, J.H., et al
	2009	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium).	Jong, D.J. de; Xie, W.; Rosenwald, A.; Chhanabhai, M.; Gaulard, P., et al
	2007	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.	Jong, D. de; Rosenwald, A.; Chhanabhai, M.; Gaulard, P.; Klapper, W., et al
	2007	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.	Ferme, C.; Eghbali, H.; Meerwaldt, J.H.; Rieux, C.; Bosq, J., et al
	2006	Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.	Noordijk, E.M.; Carde, P.; Dupouy, N.; Hagenbeek, A.; Krol, A.D.G., et al
	2004	Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma Workshop.	Kersten, M.; Jong, D. de; Raemaekers, J.M.M.; Kluin, P.; Hagenbeek, A.
	1997	Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial	Raemaekers, J.M.M.; Burgers, M.; Henry-Amar, M.; Pinna, A.; Mandard, A., et al
	1995	Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with agressive non-Hodgkin's lymphoma	Verdonck, L.F.; Putten, W.L.J. van; Hagenbeek, A.; Schouten, H.C.; Sonneveld, P., et al
	1995	Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma	Gahrton, G.; Tura, S.; Ljungman, P.; Bladé, J.; Brandt, L., et al